Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MBX vs AARD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MBX Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 4–1 Matrix Metrics)

MBX Overall Winner 6-Pillar Tally: MBX 2 – 2 AARD (2 Tie) Matrix Metrics: MBX 4 – 1 AARD

As of Nov 16, 2026, MBX Biosciences, Inc. (MBX) is the stronger overall head-to-head candidate over Aardvark Therapeutics, Inc. (AARD) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). MBX carries a Unified Composite Score of 44.9/100 (HOLD) at $53.12 (N/M Forward P/E, 0.0% operating margin), whereas AARD carries 57.5/100 (HOLD) at $1.26 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While AARD currently prints a higher short-term Unified Composite Score (57.5/100 HOLD vs. MBX 44.9/100 HOLD), MBX captures the overall institutional head-to-head verdict (4–1 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: MBX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.8); meanwhile AARD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MBX vs AARD
MBX NASDAQ Head-to-Head Winner
MBX Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$53.12
-5.04% 1D
Market Cap $2.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.58β · 66% Vol
Unified Composite Score
44.9 / 100 HOLD
Tech 42.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 48.8 · SMA20: $53.41 · SMA50: $55.62
AARD NASDAQ
Aardvark Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$1.26
-5.26% 1D
Market Cap $29.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 4.10β · 288% Vol
Unified Composite Score
57.5 / 100 HOLD
Tech 79.0 Fund 63.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -33.9%), weak momentum, RSI 31
RSI-14: 30.7 · SMA20: $1.74 · SMA50: $3.68

6-Pillar Scorecard Institutional Category Breakdown (MBX 2 – 2 AARD)

Columns: Metric · MBX · AARD
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale MBX
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $2.8B $29.1M
3. Profitability & Quality MBX
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -33.7% -66.0%
4. Balance Sheet & Cash Flow AARD
Cash Generation (TTM) N/A -$69M
Cash Flow Margin N/A N/A
Net Cash / Leverage $9.53 Book/Sh · -33.7% ROE $73M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AARD
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 64.0% (<1st %ile) 147.3% (26th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MBX (4) vs AARD (1)
Institutional Metric MBX AARD Criterion Row Edge
Market Capitalization
Scale
$2.8B $29.1M Larger Scale MBX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-33.7% -66.0% Higher ROE MBX
52-Week Range Position
Momentum
61% ($23–$73) 2% ($1–$17) Stronger Trend MBX
Beta / 30D Volatility
Risk Regime
1.58β · 66% Vol 4.10β · 288% Vol Lower Realized Risk MBX
Unified Institutional Score
Composite Signal
44.9 / 100 (HOLD) 57.5 / 100 (HOLD) Higher Composite AARD
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($9.53 Book/Sh · -33.7% ROE) -$69M ($73M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MBX +73.75 pp
MBX: +7.08% · AARD: -66.67%
3M Horizon MBX +59.36 pp
MBX: -20.14% · AARD: -79.5%
6M Horizon MBX +142.57 pp
MBX: +71.47% · AARD: -71.1%
1Y Horizon MBX +209.09 pp
MBX: +120.69% · AARD: -88.4%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBX vs AARD. Trailing 12-month operating profitability (MBX 0.0% vs AARD 0.0%) and valuation multiples (MBX N/M vs AARD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MBX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-33.7% · N/M
AARD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-66.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MBX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 64.0%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MBX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AARD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 147.3%
IV Percentile 26th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact AARD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MBX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AARD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $29.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MBX vs AARD Key Questions & Quantitative Answers

As of Nov 16, 2026, MBX Biosciences, Inc. (MBX) is the stronger overall head-to-head candidate over Aardvark Therapeutics, Inc. (AARD) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). MBX carries a Unified Composite Score of 44.9/100 (HOLD) at $53.12 (N/M Forward P/E, 0.0% operating margin), whereas AARD carries 57.5/100 (HOLD) at $1.26 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AARD currently prints a higher short-term Unified Composite Score (57.5/100 HOLD vs. MBX 44.9/100 HOLD), MBX captures the overall institutional head-to-head verdict (4–1 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: MBX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.8); meanwhile AARD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MBX leads the Growth & Scale pillar: MBX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AARD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MBX generates N/A in USD-normalized revenue versus N/A for AARD. In operating R&D and SG&A reinvestment, MBX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AARD.

MBX and AARD trade at balanced relative valuation multiples. MBX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas AARD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MBX (-33.7% ROE) versus AARD (-66.0% ROE) capital efficiency.

In options market volatility and institutional positioning, MBX carries 64.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.58β · 66% Vol realized risk). By comparison, AARD carries 147.3% implied volatility (26th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.10β · 288% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.